Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 12/20 | 0.69 |
| ▸ | CLK3 | P49761 | 11/20 | 0.69 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.69 |
| ▸ | WNT1 | P04628 | 8/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20423191 | 0.92 | CLK2 (0.68) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL18484709 | 0.92 | CLK2 (0.59) | CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL18487052 | 0.92 | CLK2 (0.67) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL18494657 | 0.91 | CLK2 (0.78) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL20397950 | 0.91 | CLK2 (0.64) | CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL20454745 | 0.90 | CLK2 (0.56) | CLK2CLK3DYRK1AWNT1 | |
| SCHEMBL20451171 | 0.89 | CLK2 (0.70) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL20775467 | 0.89 | CLK2 (0.81) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL18487053 | 0.88 | CLK2 (0.78) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL18488050 | 0.88 | CLK2 (0.70) | CLK2CLK3DYRK1AWNT1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604512-B2 | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof | SAMUMED, LLC (US) | 2020-03-31 | — | — | US | claimed |
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-09 | — | — | US | claimed |
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-09 | — | — | US | disclosed |
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222891-A1 | 3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CLK2 640/4885CLK3 573/4885DYRK1A 585/4885 |
| US-10604512-B2 | 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof | WNT1, WNT3, WNT3A | CLK2 530/4885CLK3 450/4885DYRK1A 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.